The Defense Health Agency awarded an Indefinite Delivery Contract to Kemp Proteins, LLC (doing business as Kempbio) on July 14, 2025, with a contract ceiling of $1,728,724.00 and an ultimate completion date of July 13, 2030. This is a single-award Total Small Business set-aside for hybridoma production, development, and protein purification, as well as hybridoma development studies and antibody production.
Kemp Proteins, LLC is a small disadvantaged business based in Frederick, Maryland. Place of performance is Frederick, Maryland, supporting the Defense Health Agency's biomedical research and vaccine development objectives, including work at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID).
The originating pre-solicitation, posted October 16, 2024, sought capability to develop new hybridomas from animals vaccinated at USAMRIID, produce antibodies from those hybridomas, and provide additional protein production for assays at USAMRIID. The government required rapid processing of spleen cells from vaccinated animals while maintaining viability, and contractor location within 25 miles of USAMRIID.
On August 1, 2025, the Defense Health Agency issued a $40,000 firm fixed-price delivery order under this IDIQ for hybridoma production services, scheduled for completion by July 31, 2026, to be performed at Kempbio's Frederick, Maryland facility.